Kymera Therapeutics KYMR Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -697.7%-225pp | -891.1%-335pp | -759.7%-531pp | -697.5%-488pp | -472.5%-248pp | |
| Net margin | -612%-203pp | -794.1%-318pp | -674.8%-484pp | -616%-438pp | -409.1%-214pp | |
| EBITDA margin | -681.6%-223pp | -869.9%-330pp | -740.8%-519pp | -679.4%-476pp | -459%-240pp | |
| Free cash flow margin | -474%-66.5pp | -597.7%-157pp | -526.4%-357pp | -565.7%-410pp | -407.5%-236pp | |
| Returns | ||||||
| Return on equity | -27.1%+5.1pp | -25.8%+10.6pp | -32.1%-6.1pp | -33.3%-5.1pp | -32.2%-5.8pp | |
| Return on assets | -24.3%+2.6pp | -22.9%+5.9pp | -27.6%-6.5pp | -28.1%-5.7pp | -27%-6.1pp | |
| Return on invested capital | -31.8%+5.6pp | -33.1%+11.4pp | -37.1%-5.5pp | -43.6%-11.8pp | -37.3%-7.4pp | |
| Efficiency | ||||||
| Asset turnover | 0×0.0× | 0×0.0× | 0×-0.1× | 0×-0.1× | 0.1×0.0× | |
| Liquidity | ||||||
| Current ratio | 10.8×+2.3× | 10.5×+2.9× | 7.4×-1.2× | 8.3×-0.1× | 8.5×-1.1× | |
| Quick ratio | 10.8×+2.3× | 10.5×+2.9× | 7.4×-1.2× | 8.3×-0.1× | 8.5×-1.1× | |
| Cash ratio | 2.3×+0.8× | 4.3×+2.5× | 1.6×-0.1× | 3.8×+2.7× | 1.5×-0.1× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×-0.1× | 0.1×-0.1× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | $15.79+60.9% | $18.70+67.9% | $10.84-7.6% | $12.08+28.8% | $9.81-2.4% | |
| Valuation | ||||||
| Market capitalization | $6.8B+283% | $6.22B+139% | $4.05B+12.3% | $3.07B+40.8% | $1.78B-37.5% | |
| Enterprise value | $6.74B+280% | $5.95B+131% | $4.02B+12.2% | $2.82B+28.1% | $1.78B-37.5% | |
| Price / sales | 132.1×+102× | 158.8×+103× | 92.5×+51.4× | 68.7×+44.0× | 30.2×-5.6× | |
| Price / book | 4.4×+2.2× | 3.9×+0.8× | 4.3×+0.2× | 3.2×0.0× | 2.3×-1.7× | |
| EV / sales | 130.9×+101× | 151.8×+97.1× | 91.9×+51.0× | 63.1×+38.2× | 30.2×-5.6× | |
| Free cash flow yield | -3.6%+9.9pp | -3.8%+4.2pp | -5.7%-1.6pp | -8.2%-1.9pp | -13.5%-8.7pp | |
| Earnings yield | -4.6%+8.9pp | -5%+3.6pp | -7.3%-2.6pp | -9%-1.7pp | -13.6%-8.1pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Kymera Therapeutics's ratios come from?
- Every ratio is computed from Kymera Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
